bluebird bio, Inc. (NASDAQ:BLUE) insider Jason Cole sold 1,129 shares of the firm’s stock in a transaction that occurred on Friday, January 5th. The stock was sold at an average price of $173.38, for a total value of $195,746.02. Following the sale, the insider now directly owns 19,945 shares of the company’s stock, valued at $3,458,064.10. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
bluebird bio, Inc. (NASDAQ BLUE) opened at $171.65 on Friday. bluebird bio, Inc. has a fifty-two week low of $63.10 and a fifty-two week high of $222.03. The stock has a market capitalization of $7,870.00, a price-to-earnings ratio of -24.49 and a beta of 2.08.
bluebird bio (NASDAQ:BLUE) last announced its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported ($1.73) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.68) by ($0.05). bluebird bio had a negative net margin of 883.18% and a negative return on equity of 28.79%. The company had revenue of $7.71 million during the quarter, compared to analysts’ expectations of $8.47 million. During the same quarter in the prior year, the business posted ($2.07) earnings per share. The company’s revenue was up 397.4% compared to the same quarter last year. analysts expect that bluebird bio, Inc. will post -6.72 EPS for the current year.
Several large investors have recently made changes to their positions in the company. Public Employees Retirement System of Ohio purchased a new position in shares of bluebird bio in the 3rd quarter valued at $2,725,000. Sterling Capital Management LLC purchased a new position in shares of bluebird bio in the 3rd quarter valued at $351,000. California Public Employees Retirement System increased its holdings in shares of bluebird bio by 1.5% in the 3rd quarter. California Public Employees Retirement System now owns 86,100 shares of the biotechnology company’s stock valued at $11,826,000 after acquiring an additional 1,300 shares during the period. Ladenburg Thalmann Financial Services Inc. increased its holdings in shares of bluebird bio by 454.2% in the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 992 shares of the biotechnology company’s stock valued at $136,000 after acquiring an additional 813 shares during the period. Finally, Crestline Management LP increased its holdings in shares of bluebird bio by 27.7% in the 3rd quarter. Crestline Management LP now owns 12,594 shares of the biotechnology company’s stock valued at $1,730,000 after acquiring an additional 2,735 shares during the period.
BLUE has been the topic of several research reports. Wedbush restated an “outperform” rating and set a $174.00 price objective (up from $135.00) on shares of bluebird bio in a report on Thursday, November 2nd. Cantor Fitzgerald restated a “sell” rating and set a $39.00 price objective on shares of bluebird bio in a report on Thursday, September 28th. Evercore ISI upgraded bluebird bio from an “in-line” rating to an “outperform” rating and set a $102.00 price objective on the stock in a report on Monday, October 16th. BMO Capital Markets raised their price objective on bluebird bio from $134.00 to $162.00 and gave the stock a “buy” rating in a report on Monday, October 30th. Finally, Goldman Sachs Group restated a “buy” rating and set a $186.00 price objective on shares of bluebird bio in a report on Friday, October 6th. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and thirteen have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $157.45.
COPYRIGHT VIOLATION NOTICE: This piece was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another website, it was stolen and republished in violation of United States and international trademark and copyright law. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2018/01/12/insider-selling-bluebird-bio-inc-blue-insider-sells-195746-02-in-stock.html.
About bluebird bio
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.